# Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
Canonical URL: https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-corporate-update
Ticker: KPRX
Company: Kiora Pharmaceuticals
Source: Kiora Pharmaceuticals
Published: 2026-05-08 11:00 EST
Original Source URL: https://ir.kiorapharma.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-02 11:00 EST — [Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium](https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-to-participate-in-piper-sandler-virtual-ophthalmology-symp-a9cd7ac0) — Source: Kiora Pharmaceuticals
- 2026-06-18 11:00 EST — [Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model](https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-reports-its-ion-channel-modulator-kio-300-suppressed-seizu-6aa93b6c) — Source: Kiora Pharmaceuticals
- 2026-05-08 11:00 EST — [Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Kiora Pharmaceuticals
- 2026-04-14 11:00 EST — [Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway](https://biopharmsignal.com/news/KPRX/kiora-s-phase-1-abacus-study-of-kio-301-in-retinitis-pigmentosa-published-in-nature-medicine-phase-2-trial-underway) — Source: Kiora Pharmaceuticals
- 2026-04-07 11:00 EST — [Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors](https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-announces-private-placement-for-up-to-24-million-led-by-perceptive-advisors) — Source: Kiora Pharmaceuticals
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)